A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.

被引：0
|
作者：
Elez, Elena [1 ]
Lenz, Heinz-Josef [2 ]
de Jonge, Maja [3 ]
Yaeger, Rona [4 ]
Doi, Toshihiko [5 ]
Pronk, Linda [6 ]
Teufel, Michael [7 ]
Marzin, Kristell [8 ]
Tabernero, Josep [1 ]
机构：
[1] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Erasmus Med Ctr Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Boehringer Ingelheim Espana SA, Clin Dev Oncol, Madrid, Spain
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT514
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
    Im, Seock-Ah
    Lee, SeungHwan
    Lee, Keun Wook
    Lee, Youngjoo
    Sohn, Joohyuk
    Kim, Jee Hyun
    Im, Young-Hyuck
    Park, Kyong Hwa
    Oh, Do-Youn
    Kim, Min Hwan
    Park, Yeon Hee
    Kim, Tae Min
    Choi, Yoon Ji
    Lee, Chang-Seok
    Park, Jiseon
    Baek, Nam Seok
    Choi, MiKyung
    Kim, John
    Yu, Eunyoung
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
    Subbiah, Vivek
    Awad, Mark M.
    Daud, Adil
    Gutierrez, Martin
    McDermott, Jessica Dreger
    Ou, Sai-Hong Ignatius
    Hirohashi, Tomoko
    Ingram, Kim
    Oliver, Colleen
    Smith, Derek
    Wollenberg, Lance
    Abbruzzese, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    Hollebecque, A.
    Deutsch, E.
    Massard, C.
    Gomez-Roca, C.
    Bahleda, R.
    Ribrag, V.
    Bourgier, C.
    Lazar, V.
    Lacroix, L.
    Gazzah, A.
    Varga, A.
    de Baere, T.
    Beier, F.
    Kroesser, S.
    Trang, K.
    Zenke, F. T.
    Klevesath, M.
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1530 - 1538
  • [35] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    A. Hollebecque
    E. Deutsch
    C. Massard
    C. Gomez-Roca
    R. Bahleda
    V. Ribrag
    C. Bourgier
    V. Lazar
    L. Lacroix
    A. Gazzah
    A. Varga
    T. de Baere
    F. Beier
    S. Kroesser
    K. Trang
    F. T. Zenke
    M. Klevesath
    Jean-Charles Soria
    Investigational New Drugs, 2013, 31 : 1530 - 1538
  • [36] Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
    Kollmannsberger, C.
    Hirte, H.
    Siu, L. L.
    Mazurka, J.
    Chi, K.
    Elit, L.
    Walsh, W.
    Sederias, J.
    Doyle, A.
    Eisenhauer, E. A.
    Oza, A. M.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 238 - 244
  • [37] Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
    Nemunaitis, J. J.
    Senzer, N. N.
    Kurzrock, R.
    Ng, C. S.
    Das, A.
    Atienza, R. S.
    Zang, E. A.
    Jansen, M.
    Ashworth, S.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Wang, Judy Sing-Zan
    Falchook, Gerald Steven
    Charlton, Julie
    MacDonald, Alexander
    Strickland, Donald
    Jones, Suzanne Fields
    Pease, Elizabeth J.
    Brugger, Wolfram
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Ghamande, Sharad
    Lin, Chia-Chi
    Cho, Daniel C.
    Shapiro, Geoffrey I.
    Kwak, Eunice L.
    Silverman, Michael H.
    Tseng, Yunlong
    Kuo, Min-Wen
    Mach, Wendy B.
    Hsu, Shu-Chi
    Coleman, Teresa
    Yang, James Chih-Hsin
    Cheng, Ann-Lii
    Ghalib, Mohammad H.
    Chuadhary, Imran
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 445 - 451
  • [40] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Sharad Ghamande
    Chia-Chi Lin
    Daniel C. Cho
    Geoffrey I. Shapiro
    Eunice L. Kwak
    Michael H. Silverman
    Yunlong Tseng
    Min-Wen Kuo
    Wendy B. Mach
    Shu-Chi Hsu
    Teresa Coleman
    James Chih-Hsin Yang
    Ann-Lii Cheng
    Mohammad H. Ghalib
    Imran Chuadhary
    Sanjay Goel
    Investigational New Drugs, 2014, 32 : 445 - 451
12345